Sydney-based biotech company, All G, has taken a major step in the lead-up to its first product launch – establishing a joint venture with French lactoferrin producer, Armor Protéines. The partnership will support All G’s aim to produce and commercialise recombinant human and bovine lactoferrin in 2026.
The company stated its human lactoferrin will be bio-equivalent to the native form, with greater than 95 per cent purity. Pilot-scale production of All G’s recombinant bovine lactoferrin is already complete, with plans to release a powdered form as its first product, in early 2026.
All G Foods launched in 2021 after a $15.5 million seed funding raise, announcing its precision fermentation project to create cow-free dairy and retail product, Love Buds. In October 2023, All G merged its plant-based meat business with Fënn Foods into a new company, The Aussie Plant Based Co. At the time, All G stated it would be retaining its biotechnology division and would focus on developing nature-identical dairy proteins.
The company secured regulatory approval in November 2024 to sell its recombinant lactoferrin in China, reportedly the first in the world to receive the approval. In mid-2025, All G also announced it was working with Australia’s Food and Beverage Accelerator (FaBA) to scale up production.
Armor Protéines stated on LinkedIn that combining All G's precision fermentation technology with its manufacturing expertise and connections to leading nutritional companies worldwide would enhance lactoferrin supply, quality, and global health outcomes.
“All G's approach allows for high purity and scalability, reducing costs and increasing access, while offering significant environmental benefits. With pilot-scale production complete, commercial production is set for early 2026. All G's bovine lactoferrin, bio-equivalent and highly pure, will soon be available, backed by GRAS status for adult nutrition in the US and approval for personal care sales in China.
“This partnership highlights innovation and collaboration in meeting global nutritional needs, promising a positive impact on health and sustainability worldwide,” stated Armor Protéines.
All G also plans to conduct a series B raise in the next 12 months, already drawing $10 million in convertible notes from new and existing investors.
The AFR reported these include UK cellular agricultural firm Agronomics and Doehler Ventures, the venture capital arm of German health nutrition player Doehler and Singapore-based ID Capital.
The company said on LinkedIn that the raise would support the acceleration of its commercial-scale manufacturing and the Q1 2026 launch of bovine lactoferrin into China and the US.
“These milestones reflect the work of many. Huge thank you to all of our All G team, partners, investors, and our new friends at Armor Protéines and Savencia for making this possible,” stated All G.
